Therapeutic monoclonal antibodies

@article{Breedveld2000TherapeuticMA,
  title={Therapeutic monoclonal antibodies},
  author={F. C. Breedveld},
  journal={The Lancet},
  year={2000},
  volume={355},
  pages={735-740}
}
The therapeutic potential of monoclonal antibodies (mAb) was quickly realised after the hybridoma technique allowed their development in the mid 1970s. Chimeric humanised and fully humanised mAb can now be made by recombinant engineering. About a quarter of all biotech drugs in development are mAb, and around 30 products are in use or being investigated. Licensed products are available for inhibition of alloimmune and autoimmune reactivity, and for antitumour, antiplatelet, or antiviral therapy… Expand
Monoclonal antibodies: Pharmacological relevance
TLDR
Monoclonal antibodies, a new class of biological agents, are used these days in therapeutics and diagnosis for treatment of cancer, autoimmune disorders, graft rejections, infectious diseases, asthma, and various cardiovascular disorders. Expand
The pharmacology and therapeutic applications of monoclonal antibodies
TLDR
Modifications to decrease the immunogenicity and increase the efficacy are described, with examples of optimizing their pharmacokinetic properties and enabling oral bioavailability. Expand
The Use of Drug-Monoclonal Antibody Conjugates for the Treatment of Cancer
As we reflect on the use of antibodies for immunotherapy, several important points emerge. Firstly, the polyclonal antibody (PAb) response to infectious agents such as tetanus is entirelyExpand
Monoclonal antibodies as a strategy for pulmonary diseases.
TLDR
Fundamental changes in the discovery, manufacture and safety of monoclonal antibodies have reinforced the enormous potential of these agents in treating pulmonary diseases. Expand
Engineering Monoclonal Antibodies: Production and Applications
TLDR
This chapter focuses on the in vivo and in vitro production of antibodies and the current state of antibody-based therapeutics that are presently in clinical trial. Expand
Generation, Engineering and Production of Human Antibodies Using Hucal®
TLDR
It is almost three decades since Kohler and Milstein published their work on the use of cell fusion for the production of monoclonal antibodies from immunized mice, and to date 13 therapeutic antibodies have obtained regulatory approval. Expand
Recombinant antibodies: a novel approach to cancer diagnosis and therapy
  • P. Hudson
  • Biology, Medicine
  • Expert opinion on investigational drugs
  • 2000
TLDR
The new millennium is indeed an exciting time for the design, selection and formulation of a range of new antibody-based products for cancer diagnosis and therapy, as the natural immune repertoire and somatic cell affinity maturation has been superseded by large antibody display libraries and rapid molecular evolution strategies. Expand
Drug Insight: using monoclonal antibodies to treat multiple sclerosis
TLDR
The state of development of various therapeutic mAbs for MS treatment is reviewed, including natalizumab (Tysabri®), a mAb against α4 integrin, which was very effective in suppressing MS activity, but had to be withdrawn from the market because several treated patients developed progressive multifocal leukoencephalopathy. Expand
Preparation and use of therapeutic antibodies primarily of human origin.
TLDR
Therapeutic antibodies include polyclonal immunoglobulins isolated from regular or high-titered human plasma, sera from immunized animals, and monoclonal antibodies, used for the prevention and treatment of many infectious diseases, antibody immunodeficiencies, autoimmune and inflammatory diseases, neurological disorders, and cancers. Expand
Pharmacokinetics, Pharmacodynamics and Physiologically-Based Pharmacokinetic Modelling of Monoclonal Antibodies
TLDR
There is a clear need for more complex models to improve understanding of pharmacokinetic processes and pharmacodynamic interactions of mAbs with the immune system. Expand
...
1
2
3
4
5
...

References

SHOWING 1-10 OF 30 REFERENCES
Effect of a single amino acid mutation on the activating and immunosuppressive properties of a "humanized" OKT3 monoclonal antibody.
TLDR
It is concluded that this anti-CD3 mAb bearing a single amino acid mutation in its Fc portion retains important immunosuppressive properties, while exhibiting significantly less T cell activation than OKT3 in vitro. Expand
An overview of monoclonal antibody therapy of cancer.
TLDR
Treatment of patients with advanced breast cancer using the anti-HER2/neu antibody trastuzumab (Herceptin) leads to objective responses in some patients whose tumors overexpress the HER2/NEu oncoprotein, justifying recent enthusiasm for continued efforts to refine existing approaches and to develop new antibody-based strategies to treat human malignancy. Expand
How do monoclonal antibodies induce tolerance? A role for infectious tolerance?
TLDR
The "civil service model" is proposed to explain how tolerant T cells might interfere with the responses of competent T cells in such a way as to render them tolerant. Expand
A phase I trial of humanized anti-interleukin 2 receptor antibody in renal transplantation.
TLDR
The results of this study indicate that HAT given at 1 mg/kg every other week for a total of five doses may provide therapeutic HAT concentration levels and result in good saturation of Tac receptors for at least 12 weeks after transplantation. Expand
Rituximab chimeric anti-CD20 monoclonal antibody therapy for relapsed indolent lymphoma: half of patients respond to a four-dose treatment program.
TLDR
The response rate of 48% with IDEC-C2B8 is comparable to results with single-agent cytotoxic chemotherapy, and further investigation of this agent is warranted, including its use in conjunction with standard chemotherapy. Expand
Percentage of anti-CD4 monoclonal antibody-coated lymphocytes in the rheumatoid joint is associated with clinical improvement. Implications for the development of immunotherapeutic dosing regimens.
TLDR
The results demonstrate the importance of antibody dosage and treatment regimen in determining clinical benefit and suggest that the percentage of cM-T412-coated CD4+ lymphocytes in SF may be a predictor of clinical outcome. Expand
The role of CAMPATH-1 antibodies in the treatment of lymphoid malignancies.
  • M. Dyer
  • Medicine
  • Seminars in oncology
  • 1999
TLDR
CD52 antibodies provide effective therapy for chronic leukemias, such as T-cell prolymphocytic leukemia and some subtypes of B-cell chronic lymphocyticukemia, that may be resistant to conventional chemotherapy and may allow harvesting of uncontaminated stem cells. Expand
Continuous cultures of fused cells secreting antibody of predefined specificity
TLDR
The derivation of a number of tissue culture cell lines which secrete anti-sheep red blood cell (SRBC) antibodies is described here, made by fusion of a mouse myeloma and mouse spleen cells from an immunised donor. Expand
Reduction of acute allograft rejection by daclizumab
TLDR
Administration of daclizumab in addition to dual immunosuppression therapy significantly reduced biopsy-proven acute rejection after renal transplantation, improved patient survival, and did not add to the toxicity of the immunOSuppressive regimen. Expand
Anti-tumor necrosis factor-alpha therapy of rheumatoid arthritis.
TLDR
This chapter explores the validation of the proposal that TNFα is a good therapeutic target in RA, and the rationale for anti-tumor necrosis factor-α (anti-TNFα) antibody therapy and its clinical effects, which have been remarkably reproducible, albeit temporary. Expand
...
1
2
3
...